Earnings Summary

Allogene Therapeutics, Inc.’s revenue fell -55.32% since last year same period to $0.02Mn in the Q4 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated -51.16% fall in its revenue since last 3-months.

Allogene Therapeutics, Inc.’s net profit jumped 8.08% since last year same period to $-85.78Mn in the Q4 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated -39.9% fall in its net profits since last 3-months.

Allogene Therapeutics, Inc.’s net profit margin fell -105.72% since last year same period to -408466.67% in the Q4 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated -186.46% fall in its net profit margins since last 3-months.

Allogene Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a 8.89% jump from last quarter’s estimates.

Allogene Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.41.

Allogene Therapeutics, Inc.’s earning per share (EPS) jumped 34.85% since last year same period to -0.43 in the Q4 2023. This indicates that the Allogene Therapeutics, Inc. has generated 34.85% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Allogene Therapeutics, Inc.’s return on assets (ROA) stands at -0.27.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Allogene Therapeutics, Inc.’s return on equity (ROE) stands at -0.56.